Carriers differ on code for Avastin

Why This Topic Matters

Carrier-specific billing rules can change how Avastin claims are reported and documented, and the article helps readers understand why payer guidance matters for reimbursement and compliance.

Article Sections

1. Carrier coverage and coding differences for Avastin

   Discusses how Medicare carrier policies vary for ophthalmic Avastin claims and why payer-specific instructions matter for billing. The section focuses on the general reporting framework for diagnosis, procedure, and supply claims.

2. State and carrier policy examples

   Summarizes examples of differing carrier guidance across states and contractors. It addresses documentation and claim-submission considerations tied to those policies.

3. Scheduling, compounding, and wastage

   Covers carrier and Medicare concerns about drug wastage, patient scheduling, and use of compounding practices. The section also notes related policy timing and documentation issues.

4. Avastin versus Lucentis

   Provides broader reimbursement context by comparing Avastin and Lucentis in wet AMD treatment. It discusses cost pressures, coverage trends, and why carriers may favor one approach over another.

5. New wastage guidance from Medicare

   Describes Medicare’s updated guidance on unused drugs from single-use vials and the associated manual revisions. The section places the update in the context of claim processing and drug or biological billing.